🇺🇸 Perflutren lipid microsphere in United States

28 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Back Pain — 9 reports (32.14%)
  2. Dyspnoea — 5 reports (17.86%)
  3. Cardio-Respiratory Arrest — 3 reports (10.71%)
  4. Anaphylactic Reaction — 2 reports (7.14%)
  5. Arthralgia — 2 reports (7.14%)
  6. Cough — 2 reports (7.14%)
  7. Pain In Extremity — 2 reports (7.14%)
  8. Abdominal Pain — 1 report (3.57%)
  9. Acute Coronary Syndrome — 1 report (3.57%)
  10. Acute Myocardial Infarction — 1 report (3.57%)

Source database →

Perflutren lipid microsphere in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Perflutren lipid microsphere approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Perflutren lipid microsphere in United States?

Sunnybrook Health Sciences Centre is the originator. The local marketing authorisation holder may differ — check the official source linked above.